Skip to search.
 TSX Up 0.53% TSX Ventures Up 0.23%

Celgene Corporation (CELG)

-NasdaqGS
116.85 Down 0.78(0.66%) 1:35PM EST - Nasdaq Real Time Price
Prev Close:117.63
Open:118.20
Bid:117.02 x 200
Ask:117.05 x 200
1y Target Est:138.04
Beta:1.61222
Earnings Date:Jan 26 - Jan 30 (Est.)
Day's Range:116.66 - 118.29
52wk Range:93.05 - 127.00
Volume:2,702,426
Avg Vol (3m):4,582,090
Market Cap:90.58B
P/E (ttm):44.38
EPS (ttm):2.63
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

Comparison

Symbol% ChgMkt Cap
CELGDown 0.66%90.58B
JNJDown 0.13%304.18B

Key Statistics

Forward P/E (1 yr):16.63
P/S (ttm):8.43
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-16) :5.92
Quarterly EPS Est (Dec-16) :1.59
Mean Recommendation*:1.8
PEG Ratio (5 yr expected):0.88

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell ly... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback